Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label subcutaneous RUC-4 study in STEMI patients undergoing primary PCI
NL-OMON49794Phase 2Active, not recruiting
- Sponsor
- CeleCor Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zalunfiban in myocardial infarction (MI) (3 cohorts), sponsored by CeleCor Therapeutics. Primary endpoints: TRAP-induced platelet aggregation inhibition, RUC-4 pharmacokinetics and 1 more. Started Jun 2020; status: active, not recruiting.
02
Drugs
zalunfiban
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON49794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49794.